The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
(R)-2-[4-(4-Chloro-phenyl)-3,6-dihydro-2H-pyridine-1-sulfonylamino]-N-hydroxy-propionamide ID: ALA129340
PubChem CID: 15486971
Max Phase: Preclinical
Molecular Formula: C14H18ClN3O4S
Molecular Weight: 359.84
Molecule Type: Small molecule
This compound is available for customization.
Associated Items:
Names and Identifiers Canonical SMILES: C[C@@H](NS(=O)(=O)N1CC=C(c2ccc(Cl)cc2)CC1)C(=O)NO
Standard InChI: InChI=1S/C14H18ClN3O4S/c1-10(14(19)16-20)17-23(21,22)18-8-6-12(7-9-18)11-2-4-13(15)5-3-11/h2-6,10,17,20H,7-9H2,1H3,(H,16,19)/t10-/m1/s1
Standard InChI Key: KRGLPIMLJAPCTE-SNVBAGLBSA-N
Molfile:
RDKit 2D
23 24 0 0 1 0 0 0 0 0999 V2000
3.8292 -2.2125 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
4.6542 -2.2167 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
3.0042 -2.2042 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.7667 -2.9125 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.5917 -2.9167 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.3042 -2.2917 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.9250 -1.5542 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.8292 -3.0375 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
3.8292 -1.3875 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
5.1042 -1.5167 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.1292 -2.3250 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.0417 -2.9417 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.3542 -2.2000 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
5.8667 -2.9792 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.3500 -3.6250 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
7.5667 -1.6250 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.5125 -3.0500 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.7792 -2.3917 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.3417 -3.0875 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.4000 -1.6542 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.6042 -2.4292 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
0.5250 -3.6167 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
3.0000 -3.6292 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2 1 1 0
3 1 1 0
4 5 1 0
5 3 1 0
6 14 1 0
7 10 1 0
8 1 2 0
9 1 2 0
10 2 1 0
11 6 1 0
12 2 1 0
13 4 2 0
14 12 1 0
15 4 1 0
16 11 2 0
17 11 1 0
18 19 1 0
19 17 2 0
20 16 1 0
21 18 1 0
22 15 1 0
5 23 1 6
6 7 2 0
20 18 2 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 359.84Molecular Weight (Monoisotopic): 359.0707AlogP: 1.16#Rotatable Bonds: 5Polar Surface Area: 98.74Molecular Species: NEUTRALHBA: 4HBD: 3#RO5 Violations: ┄HBA (Lipinski): 7HBD (Lipinski): 3#RO5 Violations (Lipinski): ┄CX Acidic pKa: 8.67CX Basic pKa: ┄CX LogP: 0.68CX LogD: 0.66Aromatic Rings: 1Heavy Atoms: 23QED Weighted: 0.54Np Likeness Score: -1.03
References 1. Chen JJ, Dewdney N, Lin X, Martin RL, Walker KA, Huang J, Chu F, Eugui E, Mirkovich A, Kim Y, Sarma K, Arzeno H, Van Wart HE.. (2003) Design and synthesis of orally active inhibitors of TNF synthesis as anti-rheumatoid arthritis drugs., 13 (22): [PMID:14592482 ] [10.1016/j.bmcl.2003.08.076 ]